Stay updated with breaking news from Sinopia Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN DIEGO--(BUSINESS WIRE)--Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, announced today that it has selected SB-0110 after extensive preclinical studies as its lead clinical candidate for Parkinson’s disease a...
A technique that identifies the build-up of abnormal protein deposits linked to Parkinson’s disease could aid in early detection and play a key role in the disease's clinical diagnosis and characterisation, according to research published in The Lancet Neurology journal.
July 1, 2021 July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more. $550M: VC Fund for Therapeutics for Unmet Needs venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad rang...